MedTech Industry Dynamics
MedTech Industry Dynamics
Blackstone Life Sciences has announced a $455 million collaboration with Boston Scientific to co-fund development of the VITALYST Temporary Percutaneous Transvalvular Circulatory Support System, a next-generation miniature heart pump designed to treat acute myocardial infarction cardiogenic shock.
Read MoreSuzhou Party Secretary Fan Bo met with Boston Scientific Chairman and CEO Mike Mahoney to discuss expanding the company’s investment footprint in Suzhou, deepening collaboration with local medical institutions and enterprises, and exploring AI applications in healthcare.
Read MoreBoston Scientific has appointed Joseph M. Fitzgerald as Executive Vice President and Chief Operating Officer, effective January 1, 2027, alongside a new operating structure establishing three reportable segments — Interventional Therapies, Rhythm Solutions, and MedSurg.
Read MoreIndiana Governor Mike Braun has announced that Boston Scientific will invest approximately $138 million to build a new global medical device distribution facility in Plainfield, creating up to 300 high-wage jobs and supporting the state’s life sciences sector.
Read MoreThe investment will fund purpose-built laboratories to support next-generation technology development across structural heart, cardiovascular, endoscopy, heart failure, and renal denervation, reinforcing Galway’s role as a global medtech hub.
Read MoreBoston Scientific has agreed to acquire Penumbra in a cash-and-stock deal valuing the company at approximately $14.5 billion, strengthening its position in mechanical thrombectomy and neurovascular therapies.
Read MoreBoston Scientific has entered a definitive agreement to acquire Valencia Technologies, adding an FDA-approved implantable tibial nerve stimulation system to its urology portfolio for overactive bladder treatment.
Read MoreBoston Scientific will acquire Nalu Medical for approximately $533 million, expanding its neuromodulation portfolio with battery-free peripheral nerve stimulation technology for chronic pain management.
Read More4C Medical Technologies has closed a 175 million Series D financing round led by Boston Scientific Corporation to accelerate clinical development and commercialization of its AltaValve™ System, a next-generation transcatheter mitral valve replacement (TMVR) technology for treating mitral regurgitation.
Read MoreBoston Scientific has agreed to acquire SoniVie, gaining access to its TIVUS™ Intravascular Ultrasound System for renal denervation. The $360 million deal, with up to $180 million in milestone payments, aims to expand Boston Scientific’s interventional cardiology portfolio with a minimally invasive therapy for hypertension.
Read More
